Experimental vaccines against measles in a world of changing epidemiology

Mike M. Pütz; Fabienne B. Bouche; Rik L. De Swart; Claude P. Muller

doi:10.1016/S0020-7519(03)00062-6

Experimental vaccines against measles in a world of changing epidemiology

Mike M. Pütz, Fabienne B. Bouche, Rik L. De Swart, Claude P. Muller^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

34 Citations (Scopus)

Abstract

Vaccination with the current live attenuated measles vaccine is one of the most successful and cost-effective medical interventions. However, as a result of persisting maternal antibodies and immaturity of the infant immune system, this vaccine is poorly immunogenic in children <9 months old. Immunity against the live vaccine is less robust than natural immunity and protection less durable. There may also be some concern about (vaccine) virus spread during the final stage of an eventual measles eradication program. Opinions may differ with respect to the potential threat that some of these concerns may be to the World Health Organisation goal of measles elimination, but there is a consensus that the development of new measles vaccines cannot wait. Candidate vaccines are based on viral or bacterial vectors expressing recombinant viral proteins, naked DNA, immune stimulating complexes or synthetic peptides mimicking neutralising epitopes. While some of these candidate vaccines have proven their efficacy in monkey studies, aerosol formulated live attenuated measles vaccine are evaluated in clinical trials.

Original language	English
Pages (from-to)	525-545
Number of pages	21
Journal	International Journal for Parasitology
Volume	33
Issue number	5-6
DOIs	https://doi.org/10.1016/S0020-7519(03)00062-6
Publication status	Published - May 2003
Externally published	Yes

Keywords

Bacterial vector
Epidemiology
Live attenuated vaccine
Measles virus
Recombinant protein
Synthetic peptide
Viral vector

Access to Document

10.1016/S0020-7519(03)00062-6

Cite this

@article{07ee725134024f5fac8b1cc07df735ee,

title = "Experimental vaccines against measles in a world of changing epidemiology",

abstract = "Vaccination with the current live attenuated measles vaccine is one of the most successful and cost-effective medical interventions. However, as a result of persisting maternal antibodies and immaturity of the infant immune system, this vaccine is poorly immunogenic in children <9 months old. Immunity against the live vaccine is less robust than natural immunity and protection less durable. There may also be some concern about (vaccine) virus spread during the final stage of an eventual measles eradication program. Opinions may differ with respect to the potential threat that some of these concerns may be to the World Health Organisation goal of measles elimination, but there is a consensus that the development of new measles vaccines cannot wait. Candidate vaccines are based on viral or bacterial vectors expressing recombinant viral proteins, naked DNA, immune stimulating complexes or synthetic peptides mimicking neutralising epitopes. While some of these candidate vaccines have proven their efficacy in monkey studies, aerosol formulated live attenuated measles vaccine are evaluated in clinical trials.",

keywords = "Bacterial vector, Epidemiology, Live attenuated vaccine, Measles virus, Recombinant protein, Synthetic peptide, Viral vector",

author = "P{\"u}tz, {Mike M.} and Bouche, {Fabienne B.} and {De Swart}, {Rik L.} and Muller, {Claude P.}",

note = "Funding Information: The authors acknowledge the support provided from the Centre de Recherche Public-Sant{\'e}, the European Union project BIO4-CT98-0242 and the Minist{\'e}re de la Culture, de l'Enseignement Sup{\'e}rieur et de la Recherche (Bourse BFR to MMP). This work was done by MMP in partial fulfillment of his PhD thesis.",

year = "2003",

month = may,

doi = "10.1016/S0020-7519(03)00062-6",

language = "English",

volume = "33",

pages = "525--545",

journal = "International Journal for Parasitology",

issn = "0020-7519",

publisher = "Elsevier Ltd.",

number = "5-6",

}

TY - JOUR

T1 - Experimental vaccines against measles in a world of changing epidemiology

AU - Pütz, Mike M.

AU - Bouche, Fabienne B.

AU - De Swart, Rik L.

AU - Muller, Claude P.

N1 - Funding Information: The authors acknowledge the support provided from the Centre de Recherche Public-Santé, the European Union project BIO4-CT98-0242 and the Ministére de la Culture, de l'Enseignement Supérieur et de la Recherche (Bourse BFR to MMP). This work was done by MMP in partial fulfillment of his PhD thesis.

PY - 2003/5

Y1 - 2003/5

N2 - Vaccination with the current live attenuated measles vaccine is one of the most successful and cost-effective medical interventions. However, as a result of persisting maternal antibodies and immaturity of the infant immune system, this vaccine is poorly immunogenic in children <9 months old. Immunity against the live vaccine is less robust than natural immunity and protection less durable. There may also be some concern about (vaccine) virus spread during the final stage of an eventual measles eradication program. Opinions may differ with respect to the potential threat that some of these concerns may be to the World Health Organisation goal of measles elimination, but there is a consensus that the development of new measles vaccines cannot wait. Candidate vaccines are based on viral or bacterial vectors expressing recombinant viral proteins, naked DNA, immune stimulating complexes or synthetic peptides mimicking neutralising epitopes. While some of these candidate vaccines have proven their efficacy in monkey studies, aerosol formulated live attenuated measles vaccine are evaluated in clinical trials.

AB - Vaccination with the current live attenuated measles vaccine is one of the most successful and cost-effective medical interventions. However, as a result of persisting maternal antibodies and immaturity of the infant immune system, this vaccine is poorly immunogenic in children <9 months old. Immunity against the live vaccine is less robust than natural immunity and protection less durable. There may also be some concern about (vaccine) virus spread during the final stage of an eventual measles eradication program. Opinions may differ with respect to the potential threat that some of these concerns may be to the World Health Organisation goal of measles elimination, but there is a consensus that the development of new measles vaccines cannot wait. Candidate vaccines are based on viral or bacterial vectors expressing recombinant viral proteins, naked DNA, immune stimulating complexes or synthetic peptides mimicking neutralising epitopes. While some of these candidate vaccines have proven their efficacy in monkey studies, aerosol formulated live attenuated measles vaccine are evaluated in clinical trials.

KW - Bacterial vector

KW - Epidemiology

KW - Live attenuated vaccine

KW - Measles virus

KW - Recombinant protein

KW - Synthetic peptide

KW - Viral vector

UR - http://www.scopus.com/inward/record.url?scp=0037686388&partnerID=8YFLogxK

U2 - 10.1016/S0020-7519(03)00062-6

DO - 10.1016/S0020-7519(03)00062-6

M3 - Review article

C2 - 12782053

AN - SCOPUS:0037686388

SN - 0020-7519

VL - 33

SP - 525

EP - 545

JO - International Journal for Parasitology

JF - International Journal for Parasitology

IS - 5-6

ER -

Experimental vaccines against measles in a world of changing epidemiology

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this